BriaCell Therapeutics Corp Warrants (24/02/2025) BCTXW 深 沪
等待开盘 09-23 09:30:00 美东时间
0.0383
-0.001
-2.54%
华盛通- 最 高0.0383
- 今 开0.0326
- 成交量 1.92万股
- 最 低 0.0326
- 昨 收 0.0393
- 总市值 28.87万
- 52周最高 0.70
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.0113
- 委 比 -99.57%
- 总股本 753.67万
- 历史最高 7.04
- 量 比 0.36
- 振 幅 14.50%
- 历史最低 0.0113
- 每 手 1
- 风险率 0.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BriaCell Publishes Breakthrough Cancer Immunotherapy Research In JCI Insight Journal
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the
08-26 19:35
BriaCell Announces 1-for-10 Share Consolidation To Maintain Nasdaq Listing, Effective August 25, 2025
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that
08-22 00:02
BriaCell Joins MSK's 2025 Therapeutics Accelerator to Fast-Track Cancer Immunotherapy
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to
08-13 19:36
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
BriaCell Therapeutics Corp. announced its acceptance into Memorial Sloan Kettering Cancer Center’s 2025 Therapeutics Accelerator program to accelerate the clinical development of its Bria-OTS+ immunotherapy for multiple cancers, including breast and prostate cancer. MSK’s resources will support regulatory and manufacturing efforts, with both parties expressing confidence in the therapy’s potential to advance cancer care.
08-13 11:30
BriaCell Unveils TILsRx Platform Aiming To Supercharge Immune Response Against Hard-To-Treat Cancers
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))), (TSX:BCT) ("BriaCell"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned subsidiary,
07-29 19:34
BriaCell Therapeutics Announces Closing of $15 million Public Offering
BriaCell Therapeutics Corp. has completed a best-efforts public offering of 12 million units, raising $15 million gross proceeds. Each unit includes one common share or a pre-funded warrant and one warrant. The pre-funded warrants are exercisable at $0.001, while the warrants are exercisable at $1.50 per share for five years. The company intends to use the net proceeds for working capital, general corporate purposes, and advancing business object...
07-16 20:05
BriaCell Therapeutics Reports Updated Results From Ongoing Phase 2 Study Of Bria-IMT In Combination With Check Point Inhibitor In Patients With Advanced Metastatic Breast Cancer
Sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor reduction after >18 months of treatment"Eye bulging" metastatic breast cancer patient had failed 8 prior regimens, including
07-10 19:34
BriaCell Adds Two Key Large Cancer Centers To Ongoing Pivotal Phase 3 Clinical Study; Expects Completing Patient Enrollment In Late 2025 Or Early 2026 And May Report Top Line Data As Early As H1-2026
Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 satellite locations to enroll patients in BriaCell's pivotal Phase 3 studyBriaCell's Phase 3 study currently has 58 active clinical
07-02 19:37
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
BriaCell Therapeutics has expanded its pivotal Phase 3 clinical study by adding 30 satellite locations through Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven. The study now includes 58 active sites across 15 states. BriaCell aims to complete patient enrollment by late 2025 or early 2026, with potential top-line data available as early as H1-2026. The Phase 3 trial evaluates Bria-IMT plus immune checkpoint inhibitor in adv...
07-02 11:30
BriaCell Highlights Breast Cancer Trial Data at 2025 ASCO Annual Meeting
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today presents clinical
06-02 19:34
